Here's how the leading cannabinoid-focused biotech stacks up against the top cannabis-focused REIT.
News & Analysis: GW Pharmaceuticals
These stocks were beating the S&P 500 entering July.
This is yet another reminder that all next-big-thing investments need time to mature.
Momentum for these marijuana stocks from the first half of the year should continue in the second half, too.
Hint: You won't find any Canadian marijuana stocks on this list.
It's already up 20% this year.
Here's why this shares of this cannabinoid drug company will keep soaring within the next year.
Both of these biotechs could have big catalysts on the way.
And why the federal legalization of pot in the U.S. is probably a long way off.
Here are seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.